<li>eliglustat<p>duloxetine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.</p></li><li>iobenguane i 123<p>duloxetine decreases effects of iobenguane i 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results.</p></li><li>isocarboxazid<p>isocarboxazid and duloxetine both increase  serotonin levels. Contraindicated.</p></li><li>phenelzine<p>phenelzine and duloxetine both increase  serotonin levels. Contraindicated.</p></li><li>procarbazine<p>procarbazine and duloxetine both increase  serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.</p></li><li>safinamide<p>duloxetine, safinamide.
Either increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.</p></li><li>selegiline<p>selegiline and duloxetine both increase  serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.</p></li><li>tranylcypromine<p>tranylcypromine and duloxetine both increase  serotonin levels. Contraindicated.</p></li>